Internal Medicine, Endocrinology, Diabetes, & Metabolism · Rochester, NY
NPI
1477865178
Since 2010
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
2655 Ridgeway Ave Ste 220
Rochester, NY, 14626
Phone (585) 368-4560
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
367 services
Medicare patients, 2024
201
Average age 67
Drug cost, 2024
$4.3M
7,401 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kaye Pamela Y Zozobrado was code 99214 (office e&m - established), 277 times for 161 patients. In total Kaye Pamela Y Zozobrado billed 367 services in 9 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 277 | 161 | $65.95 | $18K |
| 99232 Hospital E&M - Subsequent | Facility | 42 | 19 | $61.80 | $2,596 |
| 99204 Office E&M - New | Office | 17 | 17 | $94.15 | $1,601 |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $96.02 | $1,152 |
By year: 2022 $22K for 296 services; 2023 $24K for 336 services; 2024 $25K for 367 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kaye Pamela Y Zozobrado prescribed most often to Medicare patients was Ozempic (Semaglutide), with 921 prescriptions and refills. In total Kaye Pamela Y Zozobrado wrote 7,401 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 921 | 1,403 | 205 | $1.3M |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 612 | 1,708 | 234 | $116K |
| Levothyroxine Sodium Generic | 528 | 1,406 | 164 | $7,739 |
| Glipizide Generic | 385 | 997 | 123 | $5,528 |
| Mounjaro Tirzepatide | 322 | 421 | 63 | $443K |
| Metformin Hcl Generic | 312 | 767 | 98 | $4,069 |
| Trulicity Dulaglutide | 309 | 500 | 79 | $482K |
| Jardiance Empagliflozin | 288 | 696 | 92 | $390K |
| Metformin Hcl Er Metformin Hcl | 285 | 790 | 98 | $5,984 |
| Atorvastatin Calcium Generic | 216 | 550 | 72 | $2,849 |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 173 | 359 | 74 | $77K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 172 | 442 | 69 | $19K |
| Glipizide Er Glipizide | 119 | 306 | 37 | $2,154 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 109 | 272 | 49 | $11K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 109 | 298 | 42 | $65K |
Brand drugs: 4,044 claims; generic drugs: 2,721 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Kaye Pamela Y Zozobrado were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.